Key Stats for MRK Stock
- Past-Week Performance: 6%
- 52-Week Range: $75 to $125
- Valuation Model Target Price: $141
- Implied Upside: 18%
Analyze your favorite stocks like Merck & Co. with TIKR (It’s free) >>>
What Happened?
Merck & Co., Inc. stock rose about 6% this week, finishing near $120 per share as investors got a clearer answer to the market’s biggest question around the company: whether it can build enough new growth drivers before Keytruda, its blockbuster cancer immunotherapy, faces major patent pressure later this decade. That puts Merck in close comparison with Bristol Myers Squibb, Pfizer, Roche, AstraZeneca, Johnson & Johnson, and Gilead Sciences, because large drugmakers are being judged on patent cliffs, oncology pipelines, and whether newer medicines can replace aging blockbusters.
The stock moved higher because Merck’s oncology pipeline delivered two timely updates that made the post-Keytruda growth story look more credible. Sacituzumab tirumotecan, or sac-TMT, is an antibody-drug conjugate designed to deliver cancer therapy more directly to tumor cells, and when combined with Keytruda, it reduced the risk of disease progression or death by 65% in a late-stage China lung cancer trial with more than 400 patients. Keytruda plus Padcev also received a positive EU CHMP opinion for certain adults with muscle-invasive bladder cancer, adding another possible expansion path for Merck’s most important cancer franchise.
The pipeline news built on Merck’s Q1 earnings call, where management said total sales rose 5% to $16.3 billion, supported by Oncology, Animal Health, and new product launches. CEO Rob Davis said the company’s portfolio transformation is “well underway,” while Merck reported Keytruda family sales of $8.0 billion, up 8% excluding foreign exchange, Winrevair sales of $525 million, and Animal Health sales up 6% excluding foreign exchange. Management also narrowed and raised its full-year 2026 outlook to $65.8 billion to $67.0 billion in revenue and EPS of $5.04 to $5.16.
Recent analyst and institutional updates helped frame the rebound, but oncology progress was the main catalyst. Goldman Sachs raised its Merck price target to $137 from $133, while other recent analyst commentary continued to focus on whether Merck’s newer drugs and pipeline can offset future Keytruda pressure. Institutional updates were mixed, with some firms trimming positions and others adding shares, but the bigger takeaway is that Merck’s latest cancer data gave investors a stronger reason to look past Gardasil weakness and focus on the company’s next set of growth drivers.
Value Merck & Co. instantly (Free with TIKR) >>>
Is MRK Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 5%
- Operating Margins: 36%
- Exit P/E Multiple: 14x
Merck’s revenue outlook still depends on whether the company can turn Keytruda’s current strength into a broader oncology platform before patent pressure becomes a bigger issue.
The clearest growth drivers are Keytruda’s expansion into earlier-stage cancers, Winrevair’s adoption in pulmonary arterial hypertension, and sac-TMT’s progress as a potential antibody-drug conjugate growth engine.
See analysts’ growth forecasts and price targets for Merck & Co. (It’s free) >>>
Margins remain important because Merck is still investing heavily in R&D, product launches, and business development, so a stronger mix from oncology and specialty medicines could help protect earnings even if Gardasil remains uneven.
Based on these inputs, the model estimates a target price of around $140, implying about 18% total upside, which suggests Merck appears modestly undervalued at current prices.
At current levels, Merck’s setup depends on stronger oncology execution, Winrevair growth, pipeline readouts, and clearer proof that the company can keep growing through the post-Keytruda transition.
How Much Upside Does MRK Stock Have From Here?
Investors can estimate Merck’s potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
Value Merck & Co. in under 60 seconds with TIKR (It’s free) >>>
